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BACKGROUND: Laboratory studies suggest a possible role of magnesium intake in colorectal carcinogenesis but epidemiological
evidence is inconclusive.
METHOD: We tested magnesium–colorectal cancer hypothesis in the Nurses’ Health Study, in which 85924 women free of cancer in
1980 were followed until June 2008. Cox proportional hazards regression models were used to estimate multivariable relative risks
(MV RRs, 95% confidence intervals).
RESULTS: In the age-adjusted model, magnesium intake was significantly inversely associated with colorectal cancer risk; the RRs from
lowest to highest decile of total magnesium intake were 1.0 (ref), 0.93, 0.81, 0.72, 0.74, 0.77, 0.72, 0.75, 0.80, and 0.67 (Ptrendo0.001).
However, in the MV model adjusted for known dietary and non-dietary risk factors for colorectal cancer, the association was
significantly attenuated; the MV RRs were 1.0 (ref), 0.96, 0.85, 0.78, 0.82, 0.86, 0.84, 0.91, 1.02, and 0.93 (Ptrend¼0.77). Similarly,
magnesium intakes were significantly inversely associated with concentrations of plasma C-peptide in age-adjusted model
(Ptrend¼0.002) but not in multivariate-adjusted model (Ptrend¼0.61). Results did not differ by subsite or modified by calcium intakes
or body mass index.
CONCLUSION: These prospective results do not support an independent association of magnesium intake with either colorectal cancer
risk or plasma C-peptide levels in women.
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Colorectal cancer remains the third most common type of cancer
in both men and women in the United States and B49380
Americans are estimated to die of colorectal cancer in 2011 (Siegel
et al, 2011). Although dietary factors have been hypothesised to
play an important role in colorectal carcinogenesis (World Cancer
Research Fund, 2007), only a few dietary factors have been
consistently identified to be associated with colorectal cancer risk.
Magnesium is an essential mineral needed for 4300 biochem-
ical reactions, and plays an important role in genetic stability,
DNA synthesis, and glucose metabolism (Saris et al, 2000). Low
blood levels of magnesium (hypomagnesemia) are often seen in
individuals with type 2 diabetes, and magnesium might improve
insulin sensitivity in healthy individuals (Paolisso et al, 1992) and
in type 2 diabetics (Paolisso et al, 1989; Song et al, 2006). In
addition, magnesium intake has been shown to decrease insulin
levels (Ma et al, 1995; Fung et al, 2003; Song et al, 2004) and is
associated with a lower risk of type 2 diabetes (Lopez-Ridaura
et al, 2004; Song et al, 2004; Larsson and Wolk, 2007), a potential
risk factor for colorectal cancer (Giovannucci et al, 2010). Multiple
lines of evidence suggest a role of hyperinsulinemia and insulin
resistance in colorectal cancer (Giovannucci, 2007; Pisani, 2008),
implicating that factors such as magnesium that influence insulin
levels might affect colorectal cancer risk.
Despite the potential mechanisms, evidence from observational
studies has been inconclusive. Among the six large prospective
cohort studies published to date, one study of Swedish women
showed a significant inverse association between magnesium
intake and colorectal cancer incidence (relative risk (RR)¼0.59)
(Larsson et al, 2005); three studies (Folsom and Hong, 2006; Lin
et al, 2006; van den Brandt et al, 2007) showed non-significant
inverse associations (RRs ranged between 0.80–0.91), one study
showed a non-significant positive association (RR¼1.27) (Li et al,
2011), and one study conducted in Japan showed a significant
inverse association for men (RR¼0.48) but not for women
(RR¼1.09) (Ma et al, 2010). In addition, with similar chemical
properties, magnesium and calcium share the same homeostatic
control system and may antagonise each other physiologically
(Iseri and French, 1984). Studies showed that magnesium may
compete with calcium for intestinal absorption and transport
(Flatman, 1991). A low calcium:magnesium ratio in the lumen may
activate the transport of magnesium, whereas a high calcium
intake reduces absorption of both magnesium and calcium
(Hardwick et al, 1991). Magnesium intake has also been associated
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particularly among those with a low ratio of calcium-to-
magnesium intake (Ca:Mg) in a case–control study (Dai et al,
2007), indicating a possible interaction between calcium and
magnesium intakes in relation to colorectal cancer risk. Lack of
consideration of this potential interaction may partly explain the
inconsistency of previous findings.
The aim of this study is to examine the association between
magnesium intake and colorectal cancer risk in the Nurses’ Health
Study (NHS) and evaluate whether the association is modified by
calcium intake. In addition, given that the potential effect of
magnesium on colorectal cancer might be mediated through
improving insulin sensitivity, we also tested whether plasma levels
of C-peptide, a validated marker for insulin secretion (Bonser and
Garcia-Webb, 1984), vary by magnesium intake.
MATERIALS AND METHODS
Study population
Detailed information on the NHS has been described elsewhere
(Willett, 1998). In brief, the NHS is an ongoing cohort study
established in 1976 including 121700 married female registered
nurses at baseline who were 30–55 years old and resided in 11
states in the United States. Since 1976, biennial questionnaires
were completed by participants to collect information on
demographics, lifestyle factors, medical history, and disease
outcomes. The follow-up rate has been 490%. In this analysis,
we treated 1980 as the baseline, because that is when the
magnesium intake was first assessed. We excluded participants
with a history of cancer (except for non-melanoma skin cancer),
with ulcerative colitis, with extreme baseline total energy intake
(o600 or 43500kcal per day) or with missing or extreme
magnesium intakes (i.e., beyond 3 s.d. for log-transformed
magnesium intake), which left 85924 women for the analysis.
This study has been approved by the institutional review board at
the Brigham and Women’s Hospital (Boston, MA, USA).
Identification of incident colorectal cancer cases
Participants reported cancer and other disease outcomes in
biennial questionnaires. With permission from the study partici-
pants, researchers obtained their medical records and pathological
reports and, while blinded to exposure information, abstracted the
information on anatomic location, stage, and histological type of
the cancer. Colorectal cancer was defined according to the
International Classification of Diseases, Ninth Revision (ICD-9)
(Puckett, 1986). During the follow-up period (1980–2008), a total
of 1601 incident colorectal cancer cases were documented.
Measurement of plasma C-peptide levels
Detailed information on blood draw, transportation, and storage
in the NHS is reported in detail elsewhere (Hankinson et al,
1995). In brief, blood samples were collected from 32826 NHS
participants between 1989 and 1990. We used plasma C-peptide
data available among 1862 control participants in case–control
studies of C-peptide and diabetes, breast cancer, hypertension,
colorectal polyps, and colorectal cancer. We excluded partici-
pants with diabetes and a previous cancer diagnosis (except
non-melanoma skin cancer) before blood draw to ensure that
C-peptide levels were not influenced by these diseases. We also
restricted the analysis to the women who have been fasting at least
9h at the time of blood draw. As previously described (Wu et al,
2004), fasting levels of plasma C-peptide were measured by
enzyme-linked immunosorbent assay and a radioimmunoassay
method with all the CV o11% using blinded quality control
samples.
Assessment of magnesium intake
A validated semi-quantitative food frequency questionnaire (FFQ)
(Willett, 1998) was first administered in 1980 to collect informa-
tion on usual dietary intake over the past year and then in 1984,
1986, and every 4 years thereafter. Nine possible frequency choices
were available, ranging from ‘almost never’ to ‘6 or more times per
day’. Nutrient intakes were calculated by multiplying the frequency
of each food consumed and the nutrient content of specified
portion sizes. The food composition values for magnesium were
mainly derived from the US Department of Agriculture, Agricul-
tural Research Service (1998). In addition to foods, magnesium
intake from supplemental sources was derived using information
collected on multivitamin use and specific magnesium supple-
ments. Total intake of magnesium was calculated by summing up
the amounts from both food and supplemental sources. The
nutrients including the total and dietary magnesium intakes were
adjusted for total energy intake using the residual method (Willett,
1998). Although total magnesium intake was not evaluated in the
validation study, we have conducted validation studies on major
contributors of total magnesium (Willett et al, 1985; Salvini et al,
1989). The major contributors to (overall contributes to B60–
70%) total magnesium intake in our cohort included the cold
breakfast cereal, skim milk, coffee, multivitamins, dark bread,
nuts, spinach, broccoli, and banana. The Pearson correlation
coefficients between the mean intakes from the four 1-week dietary
records and those from the questionnaires completed after the
dietary records ranged from 0.69 for broccoli to 0.81 for skim milk
after accounting for random errors in dietary records (Salvini et al,
1989). In addition, the same FFQ (essentially after 1980 in NHS)
was used in a cohort of male health professionals, the Pearson
correlation coefficient for total magnesium between the average of
two 1-week dietary records and the FFQ completed after the
dietary records were 0.71 after accounting for random errors in
dietary records (Rimm et al, 1992).
Assessment of other variables
Information on other dietary factors such as consumption of red
meat, processed meat, alcohol, folate, calcium, vitamin D, fruits,
and vegetables was also collected from the baseline and subsequent
FFQs. In addition, we inquired about potential colorectal cancer
risk factors such as height, body weight, physical activity, cigarette
smoking, family history of colorectal cancer, aspirin use,
menopausal status, and postmenopausal hormone use in the
biennial questionnaires.
Statistical analyses
We calculated person-time for each participant from the date of
baseline questionnaire return to the date of death, colorectal
cancer diagnosis, or the end of follow-up (1 June 2008), whichever
came first. We used a Cox proportional hazards regression model
(Cox, 1972) to calculate RRs and 95% confidence intervals (CIs)
and adjusted simultaneously for age (in months) and year of
questionnaire return. We observed no violation of the proportional
hazard assumption based on the likelihood ratio test that
compared the model with and without the interaction terms
between magnesium intake and age or follow-up time.
To take advantage of the large number of cases and to examine
relative extreme intake categories, we categorised energy-adjusted
magnesium intakes into deciles based on the distribution in the
study population. We assigned the median values of these
categories and entered these values as continuous variables into
the model to conduct trend tests. In addition to adjusting for age,
in the multivariate models, we further adjusted for established
non-dietary risk factors (models 2 and 3) and additional dietary
factors (model 3 only, see Table 2 footnote for the list of these
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additional analyses in which we adjusted for multivitamin use,
total intakes of zinc, vitamin B6, vitamin B12, fibre, retinol,
b-carotene, potassium, vitamin E, saturated fat, phosphorous, and
glycemic load. Further adjustment of these factors, one at a time or
simultaneously, did not materially alter the results and thus were
not included in the final model. We modelled all covariates as
time-varying variables to take into account potential changes over
follow-up. To represent better long-term dietary intake (Hu et al,
1999) and to minimise the impact of random measurement errors
using dietary assessments, we calculated the cumulative average
intakes of total and dietary magnesium intake. In addition, we
analysed magnesium from supplemental sources using tertile
categories because intake of supplemental magnesium was low in
this study population (contributing to o8% of total magnesium).
To examine the interaction between magnesium and calcium
intakes observed in one case–control study (Dai et al, 2007) of
colorectal adenomas and hyperplastic polyps, we first tested
whether associations between total magnesium intake (in quin-
tiles) and colorectal cancer risk varied by total calcium intake
(o854, X854mg per day; median). Second, we examined whether
the associations with total magnesium intake varied by the Ca:Mg
ratio (o3.0, X3.0; median). Further, given that magnesium might
influence colorectal cancer risk by improving insulin sensitivity,
associations with magnesium intake might be stronger among
overweight/obese individuals with possible insulin resistance, as
suggested in one prior study (van den Brandt et al, 2007). We thus
evaluated whether the associations with magnesium intake varied
by body mass index (BMI) (o25, X25kgm
–2). Finally, we
examined whether associations with magnesium intake varied by
alcohol consumption (non-drinkers, 40–o10, X10g per day),
vitamin D intake (o298, X298IU per day), and physical activity
(o6, X6MET-hours per week). We used a Wald test to examine
whether the b-coefficients of the cross-product terms between
these variables and total magnesium intake were statistically
significant.
Regarding the C-peptide analysis, we log-transformed concen-
trations of C-peptide because the distribution was skewed.
We used multivariable (MV) linear regression with robust
variance (PROC MIXED with empirical statement) (White, 1980)
to investigate the association between magnesium intakes and
plasma concentrations of C-peptide. We adjusted for the same
non-dietary lifestyle and dietary factors (measured in 1990, if
applicable) as the ones listed in the full-cohort analysis.
All statistical analyses were two-sided and a P-value o0.05 was
considered statistically significant. We conducted all analyses using
the SAS software (Version 9.2, SAS Institute, Inc., Cary, NC, USA).
RESULTS
A total of 1601 incident colorectal cancer cases were documented
among 85924 women during 2238710 persons-years from 1980 to
2008. Magnesium intake increases over time in our study
population. For example, the mean intake of total magnesium
increased from 287mg per day in 1984 and 300mg per day in 1990
to 377mg per day in 2008. Dietary sources accounted for the
majority of total magnesium intake and averaged over the entire
follow-up, magnesium intake from supplemental sources con-
tributed B8% of total magnesium intake.
Selected demographic and lifestyle characteristics and potential
confounding factors were compared across the intake levels of
total and dietary magnesium (Table 1). Women with higher total
and dietary magnesium intakes were generally comparable with
women with lower intakes with respect to BMI, family history of
colorectal cancer, and total calorie intake. However, women with
higher magnesium intakes were slightly older, more likely to be
physically active and use aspirin and multivitamin as well as
consume fruits and vegetables, dietary fibre, total calcium, total
vitamin D, and total folate, but less likely to smoke and consume
alcohol, red meat, and processed meat.
Total magnesium intake was significantly associated with a
lower risk of colorectal cancer risk in age-adjusted model but the
association was attenuated after adjustment for lifestyle factors and
became largely non-significant after further adjustment for other
dietary factors (Table 2). The attenuation was mainly driven by
Table 1 Age-standardised characteristics (in 1990) by quintile (Q) of total and dietary magnesium intake in the Nurses’ Health Study
Total magnesium intake Dietary magnesium intake
Characteristics Q1 Q3 Q5 Q1 Q3 Q5
Intake of magnesium, range (median) (mg per day) o251.5 (229.0) 283.1–312.0 (297.4) 4348.9 (379.7) o244.8 (224.5) 272.5–297.0 (285.0) 4329.3 (355.2)
Age, mean (s.d.), years 54.8 (7.1) 56.6 (7.1) 58.5 (6.9) 54.7 (7.2) 56.7 (7.1) 58.8 (6.8)
Body mass index (kgm
–2), mean (s.d.)
a 25.3 (5.0) 25.1 (4.4) 24.7 (4.2) 25.3 (4.9) 25.0 (4.4) 24.6 (4.1)
Physical activity (MET-hours per week), mean (s.d.)
b 10.9 (14.2) 14.4 (17.3) 20.0 (23.0) 10.7 (14.0) 14.4 (16.7) 20.2 (23.5)
History of colorectal cancer in a parent or sibling (%) 11 11 11 11 11 11
Current smokers (%) 19 16 15 22 16 14
Regular aspirin use (%)
c 38 40 49 39 41 40
Multivitamin use (%) 24 36 50 31 38 46
Dietary intake, mean (s.d.)
Total energy (kcal per day) 1683 (431) 1716 (420) 1678 (423) 1705 (437) 1712 (420) 1682 (417)
Total carbohydrate (g per day) 194 (33) 198 (31) 210 (32) 192 (34) 197 (30) 212 (32)
Total fat (g per day) 60.0 (10.4) 56.2 (9.7) 50.6 (10.3) 60.4 (10.5) 56.3 (9.6) 49.8 (10.0)
Total protein (g per day) 69.9 (12.6) 76.3 (12.3) 81.5 (14.8) 69.1 (12.5) 76.4 (12.0) 82.2 (14.6)
Fruits and vegetables (servings per day) 3.8 (1.4) 5.1 (1.7) 6.4 (2.3) 3.8 (1.5) 5.1 (1.7) 6.4 (2.3)
Dietary fibre (g per day)
d 13.9 (2.8) 16.9 (3.4) 21.0 (5.0) 13.6 (2.7) 16.8 (3.1) 21.6 (4.9)
Alcohol consumption (g per day) 6.1 (10.6) 6.4 (9.0) 5.7 (8.2) 6.7 (11.2) 6.4 (9.2) 5.4 (7.9)
Total calcium intake (mg per day)
d 703 (243) 898 (268) 1151 (338) 723 (253) 909 (282) 1112 (334)
Total vitamin D intake (IU per day)
d 232 (143) 316 (165) 461 (219) 254 (161) 324 (177) 422 (210)
Total folate intake (mg per day)
d 297 (134) 380 (146) 526 (195) 317 (150) 389 (156) 490 (187)
Beef, pork, or lamb as a main dish (servings per week) 2.5 (1.4) 2.1 (1.2) 1.6 (1.1) 2.4 (1.3) 2.1 (1.2) 1.6 (1.0)
Processed meat intake (servings per week) 1.3 (1.4) 1.0 (1.1) 0.6 (0.8) 1.3 (1.4) 1.0 (1.0) 0.6 (0.8)
aBody mass index was calculated as weight in kilograms divided by the square of height in metres.
bMET denotes metabolic equivalent. MET-hours¼sum of the average time per
week spent in each activity MET value of each activity.
cRegular aspirin user was defined as consumption of two or more 325mg tablets per week. Non-regular user was
defined otherwise.
dNutrient values were energy-adjusted intake.
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intake. Of note, significant inverse associations with total calcium
and vitamin D intake persisted in the same MV models, suggesting
that magnesium has a weaker relation with risk of colorectal
cancer compared with calcium and vitamin D. Compared with the
first decile of total magnesium intake (D1, o229mg per day), the
MV-adjusted RRs ranged from 0.78 to 0.86 in the third to seventh
deciles (253–328mg per day), and ranged from 0.91 to 1.03 in the
top three deciles (329–1110mg per day). For colon cancer, women
in most of the categories above the bottom decile were at 10–20%
lower risk from deciles 2 to 10. Magnesium from supplemental
sources was not significantly associated with colorectal cancer risk
in either age-adjusted or MV-adjusted models (data not shown).
We observed an overall non-significant association between total
magnesium intake and risk of proximal or distal colon cancer
(data not shown). For example, compared with the first decile of
total magnesium intake, the MV RRs for distal colon cancer ranged
from 0.56 to 1.02 for deciles 2–10 (P for trend¼0.50) with the only
significant RR observed in decile 4 (RR¼0.56, 95% CI: 0.36–0.87).
For the same comparison, the MV RRs for proximal colon cancer
ranged from 0.66 to 1.04 for deciles 2–10 (P for trend¼0.26) with
the lowest RR observed in decile 6 (RR¼0.66, 95% CI: 0.46–0.96).
In addition, generally non-significant associations were seen when
we modelled magnesium intake as quintiles (data not shown).
Overall, no significant interactions were observed between total
magnesium and calcium intakes (Table 3). In addition, no clear
pattern was observed when we examined associations with total
magnesium and calcium intake in relation to colorectal cancer risk
by Ca:Mg in our study (data not shown). Moreover, the
associations were not significantly modified by BMI (o25,
X25kgm
–2), alcohol consumption (non-drinkers, 40–o10,
X10g per day), vitamin D intake (o298, X298IU per day), and
physical activity (o6, X6MET-hours per week), or menopausal
status (premenopausal, postmenopausal) (data not shown). Of
note, similar results were observed for colorectal cancer when we
categorised the BMI into three groups (o25, 25–30, X 30kgm
–2)
and sensitivity analysis of excluding diabetic women or restricting
to older women (i.e., X65years) yielded similar null results (data
not shown). Because B70–80% of colorectal cancer in developed
countries is colon cancer (Wei et al, 2004), we classified 31
colorectal cancer cases with unknown information on subsite into
the colon cancer. Sensitivity analysis of excluding these cases did
not change the results. Results for dietary magnesium intake were
similar to those observed for total magnesium intake (data not
shown). In addition, similar non-significant associations were seen
when we analysed baseline magnesium intake (data not shown).
We tested whether magnesium intake was associated with
plasma C-peptide levels among 1862 cohort members with fasting
blood samples, who were free of cancer and diabetes at the blood
draw. In the age-adjusted model, higher intakes of magnesium
were associated with lower fasting mean plasma C-peptide levels
(P for trend¼0.002) (Table 4). However, this association did not
persist after further adjustment for non-dietary lifestyle and
dietary factors (P for trend¼0.61). The non-significant association
Table 2 Relative risks (RRs, 95% CIs) for incident colorectal cancer by deciles of total magnesium intake in the Nurses’ Health Study (1980–2008)
Deciles of total magnesium intake: median (range, mg per day)
D1: 211
(o230)
D2: 242
(230–251)
D3: 260
(252–268)
D4: 275
(269–282)
D5: 289
(283–297)
D6: 304
(298–311)
D7: 318
(312–328)
D8: 336
(329–347)
D9: 359
(348–376)
D10: 401
(4376)
P for
trend
Colorectal cancer (n¼1601)
No. of cases 165 169 155 144 149 161 154 164 181 159
Person-years 216769 222057 225281 223824 226180 223364 225936 224011 226164 225126
Model 1
a 1.0
(Reference)
0.93
(0.75, 1.15)
0.81
(0.65, 1.01)
0.72
(0.58, 0.91)
0.74
(0.59, 0.92)
0.77
(0.62, 0.95)
0.72
(0.57, 0.89)
0.75
(0.60, 0.93)
0.80
(0.64, 0.98)
0.67
(0.53, 0.83)
o0.001
Model 2
b 1.0
(Reference)
0.97
(0.78, 1.20)
0.86
(0.69, 1.07)
0.78
(0.62, 0.97)
0.80
(0.64, 1.00)
0.84
(0.67, 1.05)
0.81
(0.64, 1.01)
0.85
(0.68, 1.06)
0.92
(0.74, 1.14)
0.78
(0.63, 0.98)
0.09
Model 3
c 1.0
(Reference)
0.96
(0.77, 1.19)
0.85
(0.68, 1.07)
0.78
(0.61, 0.98)
0.82
(0.64, 1.03)
0.86
(0.68, 1.10)
0.84
(0.66, 1.08)
0.91
(0.72, 1.16)
1.02
(0.81, 1.31)
0.93
(0.73, 1.22)
0.77
Colon cancer (n¼1252)
No. of cases 132 127 123 113 111 128 123 128 150 117
Person-years 216799 222088 225307 223847 226211 223394 225963 224046 226191 225165
Model 1
a 1.0
(Reference)
0.86
(0.68, 1.10)
0.79
(0.62, 1.02)
0.70
(0.54, 0.90)
0.68
(0.53, 0.87)
0.75
(0.59, 0.96)
0.70
(0.55, 0.90)
0.71
(0.56, 0.91)
0.81
(0.64, 1.02)
0.60
(0.46, 0.77)
o0.001
Model 2
b 1.0
(Reference)
0.90
(0.70, 1.15)
0.84
(0.66, 1.08)
0.74
(0.58, 0.96)
0.73
(0.57, 0.95)
0.82
(0.64, 1.05)
0.79
(0.61, 1.01)
0.80
(0.62, 1.03)
0.93
(0.73, 1.18)
0.70
(0.54, 0.90)
0.06
Model 3
c 1.0
(Reference)
0.89
(0.69, 1.14)
0.83
(0.64, 1.07)
0.74
(0.57, 0.96)
0.74
(0.56, 0.97)
0.83
(0.64, 1.09)
0.81
(0.62, 1.07)
0.84
(0.64, 1.11)
1.01
(0.77, 1.33)
0.81
(0.61, 1.10)
0.77
Rectal cancer (n¼349)
No. of cases 33 42 32 31 38 33 31 36 31 42
Person-years 216881 222161 225392 223929 226277 223469 226048 224115 226294 225227
Model 1
a 1.0
(Reference)
1.19
(0.75, 1.89)
0.86
(0.53, 1.41)
0.83
(0.51, 1.36)
0.98
(0.61, 1.57)
0.83
(0.51, 1.34)
0.77
(0.47, 1.26)
0.90
(0.56, 1.45)
0.73
(0.45, 1.20)
0.96
(0.61, 1.53)
0.31
Model 2
b 1.0
(Reference)
1.26
(0.79, 1.99)
0.93
(0.57, 1.52)
0.91
(0.56, 1.50)
1.09
(0.68, 1.75)
0.92
(0.57, 1.50)
0.88
(0.54, 1.45)
1.05
(0.65, 1.70)
0.86
(0.52, 1.42)
1.17
(0.73, 1.86)
0.97
Model 3
c 1.0
(Reference)
1.26
(0.78, 1.98)
0.94
(0.57, 1.55)
0.93
(0.55, 1.54)
1.14
(0.69, 1.87)
0.99
(0.58, 1.66)
0.97
(0.57, 1.65)
1.19
(0.71, 2.03)
1.04
(0.60, 1.82)
1.54
(0.90, 2.66)
0.23
Abbreviations: CI¼confidence interval; MET¼metabolic equivalent.
aModel 1 was adjusted for age (in months).
bModel 2 was adjusted for age (in months), smoking
before age 30 (0, 1–4, 5–10, or 410 pack-years), history of colorectal cancer in a parent or sibling (yes, no), history of endoscopy (yes, no), regular aspirin use (yes, no),
body mass index (o25, 25–o30, X30kgm
–2), physical activity (o3, 3–o27, X27 MET-hours per week), postmenopausal hormone use (premenopausal, never,
past, or current user).
cModel 3 was further adjusted for consumption of processed meat (quintiles), consumption of beef, pork, or lamb as a main dish (quintiles), alcohol
consumption (0–o5, 5–o10, 10–o15, or X15g per day), energy-adjusted total calcium intake (quintiles), total folate (quintiles), total vitamin D intake (quintiles),
and total energy intake (quintiles).
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a relative risks (RRs, 95% CIs) for the joint classification of total magnesium intake and total calcium and body mass index in the
Nurses’ Health Study (1980–2008)
Quintiles of total magnesium intake (mg per day), median (range)
229.0 (79–251.5) 268.3 (251.5–283.0) 297.4 (283.1–312.0) 328.5 (312.1–348.9) 379.7 (349.0–1100.0)
No.
cases RR (95% CI)
No.
cases RR (95% CI)
No.
cases RR (95% CI)
No.
cases RR (95% CI)
No.
cases RR (95% CI) Pinteraction
Colorectal cancer (n¼1601)
Total calcium intake 0.17
oMedian
b 174 1.0 (Reference) 198 0.84 (0.69, 1.01) 142 0.76 (0.61, 0.94) 110 0.79 (0.63, 1.00) 77 0.98 (0.75, 1.29)
XMedian
b 60 0.76 (0.57, 1.02) 101 0.66 (0.52, 0.84) 168 0.79 (0.64, 0.98) 208 0.80 (0.65, 0.98) 263 0.85 (0.69, 1.05)
BMI (kgm
–2) 0.75
o25 152 1.0 (Reference) 144 0.88 (0.69, 1.10) 169 1.02 (0.81, 1.28) 161 0.97 (0.76, 1.23) 171 1.04 (0.81, 1.33)
X25 182 1.29 (1.04, 1.61) 155 1.03 (0.82, 1.29) 141 0.94 (0.74, 1.19) 157 1.08 (0.85, 1.38) 169 1.29 (1.01, 1.64)
Colon cancer (n¼1252)
Total calcium intake 0.35
oMedian
b 208 1.0 (Reference) 156 0.87 (0.70, 1.07) 109 0.77 (0.60, 0.98) 87 0.81 (0.63, 1.06) 59 0.97 (0.72, 1.33)
XMedian
b 51 0.84 (0.61, 1.15) 80 0.66 (0.51, 0.87) 130 0.78 (0.61, 0.99) 164 0.80 (0.63, 1.01) 208 0.85 (0.67, 1.08)
BMI (kgm
–2) 0.78
o25 120 1.0 (Reference) 111 0.84 (0.64, 1.09) 131 0.98 (0.76, 1.27) 125 0.91 (0.70, 1.19) 134 0.98 (0.74, 1.30)
X25 139 1.22 (0.96, 1.57) 125 1.02 (0.79, 1.32) 108 0.88 (0.67, 1.15) 126 1.06 (0.81, 1.38) 133 1.23 (0.93, 1.62)
Rectal cancer (n¼349)
Total calcium intake 0.23
oMedian
b 66 1.0 (Reference) 33 0.74 (0.50, 1.10) 38 0.74 (0.48, 1.14) 36 0.72 (0.44, 1.19) 37 1.03 (0.59, 1.80)
XMedian
b 9 0.51 (0.25, 1.03) 30 0.64 (0.38, 1.07) 33 0.82 (0.53, 1.27) 31 0.81 (0.52, 1.25) 36 0.85 (0.55, 1.32)
BMI (kgm
–2) 0.19
o25 32 1.0 (Reference) 42 1.04 (0.63, 1.71) 33 1.19 (0.73, 1.94) 23 1.20 (0.72, 2.00) 18 1.29 (0.75, 2.19)
X25 43 1.59 (1.00, 2.53) 21 1.05 (0.63, 1.74) 38 1.17 (0.71, 1.96) 44 1.19 (0.70, 2.01) 55 1.55 (0.91, 2.65)
Abbreviations: CI¼confidence interval; BMI¼body mass index; MET¼metabolic equivalent.
aAdjusted for age (in months), smoking before age 30 (0, 1–4, 5–10, or 410
pack-years), history of colorectal cancer in a parent or sibling (yes, no), history of endoscopy (yes, no), regular aspirin use (yes, no), BMI (o25, 25–o30, X30kgm
–2, not for
analysis of BMI), physical activity (o3, 3–o27, X27 MET-hours per week), postmenopausal hormone use (premenopausal, never, past, or current user), consumption of
processed meat (quintiles), consumption of beef, pork, or lamb as a main dish (quintiles), alcohol consumption (0–o5, 5–o10, 10–o15, or X15g per day), energy-adjusted
total calcium intake (quintiles; not for analysis of calcium), total folate (quintiles), total vitamin D intake (quintiles), and total energy intake (quintiles).
bMedian value 854mg per
day was used.
Table 4 Geometric means (s.d.) for fasting C-peptide (ngml
–1) for 1862 women by deciles (D) of magnesium intake in the Nurses’ Health Study
Magnesium deciles
Intakes D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 P for trend
Total magnesium
a (mg per day)
Medians 211 240 258 272 287 304 322 344 373 434
No. of controls 197 187 188 184 180 187 186 173 199 183
Model 1
b 1.51
(1.38, 1.66)
1.46
(1.34, 1.58)
1.34
(1.22, 1.47)
1.33
(1.21, 1.48)
1.41
(1.28, 1.56)
1.35
(1.24, 1.47)
1.41
(1.29, 1.53)
1.35
(1.24, 1.48)
1.30
(1.21, 1.41)
1.26
(1.17, 1.36)
0.002
Model 2
c 1.65
(1.50, 1.81)
1.63
(1.50, 1.78)
1.41
(1.28, 1.55)
1.53
(1.38, 1.70)
1.58
(1.43, 1.74)
1.54
(1.41, 1.69)
1.62
(1.47, 1.77)
1.57
(1.43, 1.72)
1.53
(1.41, 1.67)
1.52
(1.40, 1.66)
0.39
Model 3
d 1.61
(1.45, 1.78)
1.59
(1.45, 1.74)
1.40
(1.27, 1.55)
1.49
(1.33, 1.67)
1.55
(1.41, 1.71)
1.51
(1.38, 1.66)
1.57
(1.42, 1.73)
1.57
(1.42, 1.73)
1.51
(1.38, 1.65)
1.50
(1.36, 1.66)
0.61
Dietary magnesium
a (mg per day)
Medians 208 237 252 2656 278 294 308 326 347 387
No. of controls 198 183 190 177 201 193 171 188 174 189
Model 1
b 1.52
(1.40, 1.65)
1.42
(1.29, 1.55)
1.44
(1.33, 1.56)
1.33
(1.20, 1.48)
1.41
(1.30, 1.53)
1.37
(1.25, 1.49)
1.29
(1.18, 1.41)
1.41
(1.30, 1.53)
1.26
(1.15, 1.37)
1.27
(1.18, 1.38)
0.0007
Model 2
c 1.66
(1.53, 1.80)
1.60
(1.45, 1.76)
1.54
(1.41, 1.68)
1.46
(1.31, 1.63)
1.62
(1.49, 1.76)
1.56
(1.42, 1.71)
1.48
(1.35, 1.62)
1.63
(1.49, 1.79)
1.47
(1.34, 1.61)
1.54
(1.41, 1.68)
0.21
Model 3
d 1.63
(1.49, 1.79)
1.56
(1.41, 1.72)
1.52
(1.39, 1.68)
1.44
(1.29, 1.61)
1.59
(1.46, 1.74)
1.53
(1.39, 1.70)
1.43
(1.30, 1.58)
1.58
(1.43, 1.75)
1.44
(1.31, 1.60)
1.50
(1.36, 1.66)
0.24
Abbreviation: MET¼metabolic equivalent.
aThe magnesium intakes were based on 1990 data from the Nurses’ Health Study. Geometric mean values were centred at age
60 years.
bModel 1 was adjusted for age at blood draw (in months).
cModel 2 was adjusted for age at blood draw (in months), smoking before age 30 (0, 1–4, 5–10, or
410 pack-years), history of colorectal cancer in a parent or sibling (yes, no), history of endoscopy (yes, no), regular aspirin use (yes, no), body mass index (o25, 25–o30,
X30kgm
–2), physical activity (o3, 3–o27, X27 MET-hours per week), postmenopausal hormone use (premenopausal, never, past, or current user).
dModel 3 was further
adjusted for consumption of processed meat (quintiles), consumption of beef, pork, or lamb as a main dish (quintiles), alcohol consumption (0–o5, 5–o10, 10–o15,
or X15g per day), energy-adjusted total calcium intake (quintiles), total folate (quintiles), total vitamin D intake (quintiles), and total energy intake (quintiles).
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stratified by BMI (o25, 25–30, X 30kgm
–2) (data not shown).
DISCUSSION
In this large prospective study of middle-aged to older American
women, we observed no significant association between magne-
sium intakes with risk of colorectal cancer. In addition, we found
no significant modification by BMI, alcohol consumption, calcium
intake, vitamin D intake, physical activity, and menopausal status.
Moreover, magnesium intake was not significantly independently
associated with fasting plasma concentrations of C-peptide, a
marker for insulin secretion.
The current epidemiologic data regarding the association
between magnesium intake and colorectal cancer incidence have
been mixed. Among the six studies (Larsson et al, 2005; Folsom
and Hong, 2006; Lin et al, 2006; van den Brandt et al, 2007; Ma
et al, 2010; Li et al, 2011), an inverse association was first suggested
in a cohort of Swedish women for both colon (X255 vs o209,
RR¼0.66, 95% CI: 0.41–1.07, P for trend¼0.08) and rectal cancer
(same comparison, RR¼0.45, 95% CI: 0.22–0.89, P for trend
¼0.02) (Larsson et al, 2005). The Iowa Women’s Health Study
subsequently reported that total magnesium intake was associated
with a lower risk of colon cancer (extreme quintile comparison,
4351 vs o245mg per day, RR¼0.77, 95% CI: 0.58–1.03, P for
trend¼0.04) but not with rectal cancer (same comparison,
RR¼0.95, 95% CI: 0.56–1.60, P for trend¼0.96) (Folsom and
Hong, 2006). No associations were observed in the Women’s
Health Study (extreme quintile comparison, 4392 vs o279mg per
day, RR¼0.97, 95% CI: 0.63–1.49, P for trend¼0.88) (Lin et al,
2006), the Netherlands Cohort Study (extreme quintile compar-
ison, 4373 vs o286mg per day, RR¼0.91, 95% CI: 0.62–1.35,
P for trend¼0.50 for men; 4326 vs o256, RR¼0.89, 95% CI:
0.59–1.35, P for trend¼0.77 for women ) (van den Brandt et al,
2007), and a cohort study conducted in Germany (X381 vs
o261mg per day, RR¼1.27, 95% CI: 0.76–2.10, P for trend¼0.41)
(Li et al, 2011). In the only study conducted in an Asian population, a
significant inverse association between dietary magnesium intake and
colorectal cancer risk was observed in Japanese men (X327 vs
o238mg per day, RR¼0.65, 95% CI: 0.40–1.03, P for trend¼0.04)
but not in women (X316 vs o237mg per day, RR¼1.15, 95% CI:
0.60–2.21, P for trend¼0.69) (Ma et al,2 0 1 0 ) .O fn o t e ,a m o n gt h e s e
cohorts, the intake level and the inter-quintile intake range was the
lowest in the Swedish study (Larsson et al, 2005) (209–255mg per
day) compared with all other studies (minimum inter-quintile intake
of 245 and maximum of 392mg per day). The inverse associations
observed in the Swedish study (Larsson et al, 2005) suggest that
individual’s colorectal risk may be increased only at very low
magnesium intake. In support of this, Ma et al (2006) reported that
magnesium intake up to 325mg per day was associated with
insulin sensitivity but provide no further benefit above this level.
The efficacy and safety of magnesium from supplements on
colorectal cancer risk is unclear although some animal data showed
that magnesium supplementation may decrease the occurrence of
experimentally induced colon cancer by potentially binding to
potentially carcinogenic bile acids (Mori et al, 1993). Current human
data on magnesium supplements are sparse and low prevalence of
magnesium supplementation use (i.e., o10%) in our study and the
earlier studies (Folsom and Hong, 2006; Lin et al, 2006; van den
Brandt et al, 2007) limited our ability to draw firm conclusions
regarding magnesium supplement use and colorectal cancer risk.
A recent case–control study indicated a possible interaction
between calcium and magnesium intake in relation to risk of
colorectal adenoma and hyperplastic polyps (Dai et al, 2007). In
that study, a significant inverse association was observed with
magnesium intake only among the participants with low calcium
to magnesium ratio (Dai et al, 2007), supporting their hypothesis
that a low Ca:Mg intake ratio may promote magnesium
transportation. We evaluated this hypothesis and found no overall
clear pattern. Nonetheless, the influence of increasing Ca:Mg
intake ratio on health is unclear. A high Ca:Mg intake ratio,
possibly caused by low dietary magnesium intake and a steady
increase in calcium intake, might link to insulin resistance,
hyperinsulinemia, type 2 diabetes, and cardiovascular diseases
(Rosanoff, 2010). The adequacy of calcium and magnesium and
their balance for optimal health warrant future investigation.
Magnesium as a cofactor for several enzymes for glucose
metabolism and the inverse association reported between magne-
sium intake and risk of type 2 diabetes in a meta-analysis of seven
cohort studies (Larsson and Wolk, 2007) supports a potential role
of magnesium in glucose homeostasis and insulin action. In
addition, higher magnesium intake has been shown to be
associated with lower fasting insulin concentrations among women
without diabetes (Fung et al, 2003). We observed a significant
inverse association between magnesium intake and levels of
plasma C-peptide, a marker of insulin secretion (Bonser and
Garcia-Webb, 1984), but results were significantly attenuated in
MV-adjusted model. In addition, individuals with insulin resis-
tance might benefit from magnesium intake but observational
studies have shown mixed results. In contrast to the significant
inverse trends between magnesium intake and colorectal cancer
risk observed in overweight individuals in the study conducted in
the Netherlands (van den Brandt et al, 2007), we found no clear
indication of this interaction between magnesium intake and BMI,
which was consistent with the results from three other studies
(Folsom and Hong, 2006; Lin et al, 2006; Ma et al, 2010).
Several limitations of our study merit consideration. Measure-
ment error associated with assessing magnesium intake exists. In
contrast to using a single baseline measurement of magnesium
intake in the majority of early studies, the comprehensive updated
measurements of magnesium intake used in the current study
allowed us not only to reduce measurement error but also take into
account changes in intake over time. In addition, results from
multivariate models in which we controlled for non-dietary and
other dietary factors need to be interpreted with caution because
magnesium intake is correlated with intake of calcium (r¼0.5)
and other nutrients. As with earlier studies (Folsom and Hong,
2006; Lin et al, 2006; van den Brandt et al, 2007), we had limited
power to evaluate the association with magnesium from supple-
mental sources. Although the overall study is large, we had limited
power to examine potential interactions, especially with calcium.
Major strengths of our study included its large size, prospective
design, repeated measurements, long follow-up time, and high
follow-up rate. In addition, the fasting pre-diagnostic plasma
C-peptide levels among non-diabetic individuals are more likely to
represent the long-term insulin levels because the levels are less
likely influenced by disease status.
In summary, although our study among middle-aged US women
did not support an overall independent and linear association of
magnesium intake with colorectal cancer risk, we cannot rule out a
possible non-linear relationship, especially for colon cancer and
among individuals with low calcium intake. A meta-analysis and
studies of genetic variants of the magnesium metabolising pathway
might be informative.
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